Morningside

Xealth is a digital health technology company that provides a platform enabling clinicians to integrate, prescribe, and monitor digital health tools within electronic health record workflows. The Xealth platform helps care teams select appropriate digital health tools and programs, deliver orders to patients via email or patient portal, and track patient engagement and utilization, at both individual and system levels. The platform supports patient education and connects with online third-party apps and programs, device monitoring, and non-clinical services such as ride-sharing, food delivery, and e-commerce recommendations. Founded in 2016 and based in Seattle, Xealth focuses on scaling healthcare workflows by automating the prescription and monitoring of digital health tools to improve engagement and outcomes.

Accro Bioscience is a biopharmaceutical company that specializes in the development of innovative small molecule drugs aimed at treating inflammatory and autoimmune diseases, as well as cancer. The company conducts research on the molecular mechanisms underlying regulated cell death processes, including necroptosis, pyroptosis, and ferroptosis. By understanding these mechanisms, Accro Bioscience aims to enhance current therapeutic approaches and address specific pathologies associated with various human diseases.

League is a technology company specializing in next-generation healthcare consumer experiences. It offers a platform that creates personalized digital health experiences, driving measurable results.

SimpliFed is a telehealth company that offers virtual breastfeeding support and broader maternal care services to new and pregnant parents. Founded in 2020, it addresses challenges such as sleep deprivation, uncertainty, and complex infant nutrition questions. The company builds trusted relationships with parents and partners with healthcare payers and providers to deliver a comprehensive maternal health operating system covering pregnancy, postpartum, and baby feeding.

AdvanCell is a clinical-stage company developing novel radiopharmaceuticals for cancer treatment. It specializes in attaching alpha-emitting isotopes to molecules that deliver cytotoxic radiation directly to tumors, aiming to provide safe and effective therapies for multiple cancer types.

Geneoscopy develops non-invasive diagnostics using stool-derived eukaryotic RNA to prevent, detect, and guide treatment for gastrointestinal diseases. Its platform technology enables early-stage detection of colorectal cancer neoplasms and improves screening compliance.

Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.

CairnSurgical develops patient-specific image guidance tools to improve precision in cancer surgery. The company designs and manufactures devices derived from individual imaging data and uses 3D printing technologies to create guides that help healthcare professionals plan and execute surgical interventions with higher accuracy, aiming to achieve better clinical outcomes for cancer patients.

Kappa Pay is a fintech platform that utilizes blockchain technology to streamline payment processes for both local and cross-border transactions. The company aims to provide an affordable and reliable solution for individuals and merchants, facilitating seamless payments that resemble the simplicity of sending a message. By focusing on removing friction and barriers in financial transactions, Kappa enables users to send and receive money globally with higher transaction limits, enhancing the overall efficiency of the payment experience.

ENYO Pharma is a clinical-stage biopharmaceutical company headquartered in Lyon, France, with additional operations in Melbourne, Australia. Founded in 2014, it focuses on discovering and developing antiviral therapies by studying virus-host interactions within the human protein interaction network and leveraging its drug discovery platform to identify intracellular targets and molecules. The company's pipeline includes EYP001, a lead compound that modulates FXR, aiming to reduce the hepatitis B virus cccDNA reservoir and suppress viral transcription, and EYP002 for preclinical development. It also conducts toxicology testing for antiviral candidates against multiple viruses, including influenza, and pursues additional programs aimed at chronic hepatitis B and other infectious diseases. ENYO collaborates with researchers and institutions in Lyon, including Inserm and related biopole ecosystems, to advance its programs through early-stage clinical development and preclinical studies. The company aims to translate virus-host interaction biology into therapeutics for infectious diseases and related liver and metabolic conditions.

Suvera develops a virtual care platform that empowers primary care providers to deliver effective remote management for patients with long-term conditions. The platform aims to improve patient outcomes by reducing hospital admissions and doctor appointments, while promoting better health.

Pelicargo operates a digital platform that streamlines air freight procurement for freight forwarders and airlines. It offers real-time spot rate access from global carriers, intuitive quoting tools, and personalized support to enhance efficiency in managing complex air shipments.

FireCyte Therapeutics is developing treatments targeting microglia and neuroinflammation for progressive neurodegenerative eye diseases such as glaucoma and age-related macular degeneration.

Jitjatjo is a workforce management solutions provider initially focused on the Leisure & Hospitality and Retail industries. It offers on-demand staffing through its contingent labor marketplace, Ondemand, and empowers enterprise clients to transform their labor models through Network, its SaaS platform.

Angitia Biopharmaceuticals is a global clinical-stage biotechnology company focused on discovering and developing therapeutics for musculoskeletal diseases, specifically targeting bone, muscle, and joint conditions. Through its research and development activities, it aims to deliver breakthrough therapies that address unmet needs and improve outcomes for patients with severe musculoskeletal disorders.

Epigenic Therapeutics is a biotechnology company focused on developing gene editing therapies that leverage gene-silencing technology to address a range of diseases. The firm specializes in epigenome editing, aiming to regulate various conditions, including those related to ophthalmology, neurodegeneration, metabolism, and rare diseases. By creating innovative treatments, Epigenic Therapeutics seeks to offer effective solutions for patients suffering from chronic and severe health issues.

GaeaStar manufactures eco-friendly single-use cups using patented technology that prints thin clay cups from locally sourced materials. This innovative approach aims to reduce waste and promote sustainability in the face of increasing pressure to move away from traditional, non-recyclable cups.

Cognito Therapeutics, established in 2016 and headquartered in Newton Centre, Massachusetts, with additional locations in San Francisco and Boston, is a clinical-stage neurotechnology company. It specializes in developing non-invasive, device-based therapies to treat neurodegenerative diseases, with a primary focus on Alzheimer's disease. The company's innovative approach involves using induced brain wave oscillations to reactivate the immune system in the brain, aiming to reduce typical disease hallmarks such as amyloid plaques and tau tangles. Co-founded by MIT professors Li-Huei Tsai and Ed Boyden, Cognito's lead therapy is currently in a pivotal study for Alzheimer's, and has been recognized as a Breakthrough Device by the FDA.

PhagePharm is a company focused on the industrialization of bacteriophages, specifically developing antibiotics and phage products for the animal breeding industry. The organization creates a range of effective disease immunization solutions aimed at enhancing the health of animals and supporting the growth of the animal breeding and agricultural sectors. By providing innovative health products, PhagePharm aims to improve overall animal health and productivity within these industries.

LumiraDx Ltd, incorporated in 2016 and based in London, United Kingdom, is a next-generation point-of-care diagnostics company. It specializes in manufacturing an innovative diagnostic platform that provides a wide range of tests with lab-comparable performance. LumiraDx aims to transform healthcare by offering solutions that facilitate integrated, patient-centered care, enhancing safety, efficiency, and health outcomes. The company's diagnostic system includes a portable instrument, low-cost test strips, and seamless digital connectivity, making diagnostic-led care simpler and more accessible. LumiraDx operates in multiple countries, including the United States, Italy, Germany, and Sweden, with a significant portion of its revenue generated from the U.S. market.

Founded in 2015, Evonetix develops innovative technology for parallel DNA synthesis on silicon arrays, facilitating synthetic biology research. Based in Little Chesterford, UK, the company combines scientific and engineering expertise to advance DNA synthesis capabilities.

Zhide New Energy is a developer of approaches to synthetize new silicon anode materials. They focuses on silicon technology that can be applied to produce new materials. They also produce battery with high energy density and low cost. They manufactures battery for 3C and EV. They provide batteries for fields, such as electric vehicles, consumer electronics, house power storage, and wearable devices.

Mevox is a biotechnology company that develops vaccine innovation technology. Its platform translates molecular characterization, design, and engineering into conformationally precise and optimized protein antigens. The technology aims to produce antigens with higher neutralizing antibody levels than existing vaccines, enabling the development of established vaccines to address significant unmet medical needs and protect global health.

WiseConn is a technology company focused on addressing resource management challenges, particularly in the areas of water usage in agriculture, mining, and hydrology. The company has developed a comprehensive platform that integrates wireless hardware and accessible software to facilitate real-time monitoring and control of water and other fluids. This platform allows users to manage various aspects of agricultural operations, including fertigation, climate conditions, soil moisture, and plant health. By enabling field managers to wirelessly monitor and automate irrigation systems, WiseConn aims to enhance efficiency, reduce water consumption, and improve overall productivity in resource-sensitive environments.

Resilience Lab is a company focused on enhancing the delivery of mental health care through innovative clinical services and therapy centers. It aims to expand access to mental health resources by offering a range of services, including individual, couple, and family therapy, as well as parenting support, nutrition therapy, and weight management. By providing personalized and high-quality care, Resilience Lab seeks to empower individuals and families to achieve sustainable mental and physical well-being. The company emphasizes a collaborative approach among clinicians to ensure that clients receive comprehensive support tailored to their unique needs.

Founded in 2013 and based in Cambridge, Massachusetts, CollegeVine is a technology company that specializes in developing artificial intelligence platforms to replace administrative tasks within the higher education sector. Its primary goal is to save time and money for universities globally by deploying safe AI agents, aiming to make higher education sustainable and efficient.

Valitor, Inc. is a biotechnology company based in Berkeley, California, founded in 2010. The company specializes in the development of advanced, protein-based drugs and has established innovative methods for modifying therapeutic proteins. This technology enables enhanced control over pharmacokinetics, target specificity, and bioactivity, thus improving the pharmacological properties of existing and emerging protein drugs. Valitor's research and development efforts are focused on three key areas: dermatology, ophthalmology, and orthopedics, where they are advancing novel drug products designed to address unmet medical needs in these fields.

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, focused on the discovery and development of small molecule therapeutics aimed at addressing unmet medical needs in autoimmunity and cancer. The company's lead product candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for five autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials in systemic lupus erythematosus. In addition to KZR-616, Kezar is developing KZR-261, which targets oncology and autoimmune indications. Founded in 2015, the company leverages innovative research in protein homeostasis and has established a pipeline of potential therapies to advance treatment options for patients.

Kappa Pay is a fintech platform that utilizes blockchain technology to streamline payment processes for both local and cross-border transactions. The company aims to provide an affordable and reliable solution for individuals and merchants, facilitating seamless payments that resemble the simplicity of sending a message. By focusing on removing friction and barriers in financial transactions, Kappa enables users to send and receive money globally with higher transaction limits, enhancing the overall efficiency of the payment experience.

AdvanCell is a clinical-stage company developing novel radiopharmaceuticals for cancer treatment. It specializes in attaching alpha-emitting isotopes to molecules that deliver cytotoxic radiation directly to tumors, aiming to provide safe and effective therapies for multiple cancer types.

GreenLight Biosciences is a biotechnology company specializing in RNA-based solutions for agriculture and pharmaceutical applications. It develops mRNA vaccines, including COVID-19 candidates, and offers sustainable crop protection technologies using its proprietary cell-free production platform.

Epigenic Therapeutics is a biotechnology company focused on developing gene editing therapies that leverage gene-silencing technology to address a range of diseases. The firm specializes in epigenome editing, aiming to regulate various conditions, including those related to ophthalmology, neurodegeneration, metabolism, and rare diseases. By creating innovative treatments, Epigenic Therapeutics seeks to offer effective solutions for patients suffering from chronic and severe health issues.

Bevi develops bottle-less water dispensers for offices and commercial spaces that dispense beverages made from filtered tap water with natural flavors, including real fruit essences. The systems allow users to customize drinks and view nutrition information, while the company emphasizes tracking environmental impact and reducing waste from bottled beverages. The technology is designed to run on the municipal water supply, aiming to transform beverage delivery by offering eco-friendly, healthy hydration options on site.

Airspace Link designs and develops an enterprise SAAS platform for managing local government airspace for drones. It offers solutions such as AirRegistry for automated drone delivery approvals, AirInspect for inspection tools, AirHub for network generation, and AirLink for inter-governmental airspace sharing. Founded in 2018, the company is based in Plymouth, Michigan.

Eko Health is a leading digital health company advancing how healthcare professionals detect and monitor heart and lung disease with its portfolio of digital stethoscopes, patient and provider software, and AI-powered analysis. Its FDA-cleared platform is used by hundreds of thousands of healthcare professionals worldwide, allowing them to detect earlier and with higher accuracy, diagnose with more confidence, manage treatment effectively, and ultimately give their patients the best care possible. Eko Health is headquartered in Emeryville, California, with over $125 million in funding from Highland Capital Partners, Questa Capital, Artis Ventures, DigiTx Partners, NTTVC, Morningside Technology Ventures Limited, Mayo Clinic, Sutter Health, and others. For more information visit www.ekohealth.com.

Adiso Therapeutics is a biotechnology company focused on developing therapies for inflammatory diseases. It is building a pipeline of small molecule drugs and single strain live biotherapeutic products with novel mechanisms of action to address disease progression and safety limitations of current treatments. The platform includes gut-restricted neutrophil modulators and inflammasome inhibitors, designed to provide improved efficacy with reduced systemic exposure. The research targets conditions such as ulcerative colitis, other inflammatory and neuroinflammatory diseases, and respiratory conditions, aiming to offer multi-modal treatment options. By combining different modalities within a single platform, Adiso seeks to deliver safer, more effective therapies for patients.

Cydar Medical develops computer vision software that provides real-time automated 3D overlays during X-ray guided procedures. This enables clinicians to focus on patients rather than adjusting displays, with high-performance updates facilitated by cloud supercomputing.

Curve Health, Inc. is an innovative online platform focused on enhancing senior care by integrating telemedicine, health information exchange, smart billing, and predictive analytics. Established in 2020 and headquartered in New York, the company aims to improve healthcare delivery for seniors by facilitating remote patient care across various settings, including skilled nursing facilities, homes, and ambulances. Curve Health's platform has successfully reduced patient transfers from skilled nursing facilities to emergency departments by over 50%. It streamlines care coordination between hospital systems and post-acute facilities, automates billing processes, and enhances the tracking of patient diagnoses and outcomes. By bridging existing gaps in healthcare delivery, Curve Health seeks to optimize resource allocation, minimize readmissions, and ensure a seamless experience for patients, ultimately leading to improved care quality and financial returns for healthcare providers.

GreenLight Biosciences is a biotechnology company specializing in RNA-based solutions for agriculture and pharmaceutical applications. It develops mRNA vaccines, including COVID-19 candidates, and offers sustainable crop protection technologies using its proprietary cell-free production platform.

Casana, officially known as Heart Health Intelligence Inc., is a healthcare technology company based in Rochester, New York, founded in 2018. It specializes in developing innovative solutions for heart health monitoring, primarily through its flagship product, the Heart Seat. This smart toilet seat is designed to facilitate effortless and continuous in-home health monitoring by capturing essential clinical measurements such as heart rate, blood pressure, cardiac output, ECG, and blood oxygenation. The Heart Seat integrates advanced sensors, including a single-lead ECG, embedded photoplethysmogram LEDs, and sensitive weight sensors, to monitor cardiac activity. By offering a cloud-connected platform, Casana enables healthcare practitioners to track patients' cardiac health beyond traditional clinical settings, thereby enhancing the management of chronic conditions and improving patient outcomes through reliable and consistent vital signs analysis.

Big Health is a digital therapeutics company headquartered in London, United Kingdom, that specializes in developing and marketing innovative behavioral health programs. The company's flagship product, Sleepio, is a digital sleep improvement program that employs Cognitive Behavioral Therapy techniques to address and personalize sleep disorders. By offering a fully automated healthcare portal, Big Health delivers highly personalized digital therapeutics and behavioral programs aimed at tackling various mental health issues. Their approach combines medical consultation with user-friendly technology, enabling individuals to effectively manage and overcome sleep-related disorders in an efficient manner.

Virtue Diagnostics (Suzhou) Co., Ltd. is an in vitro diagnostic (IVD) company based in Suzhou, China, with a research and development office in Singapore. Founded in 2019, the company specializes in developing advanced diagnostic platforms for the detection of infectious diseases, cancer, and chronic diseases. Its technology offerings include clinical mass spectrometry, multiplex immunohistochemistry for pathology-based cancer detection, and a molecular and immunoassay platform. Virtue Diagnostics aims to enhance diagnostic capabilities and improve patient outcomes through its innovative solutions.

Almond FinTech is a blockchain-based cross-border payments platform that connects a global network of financial institutions to enable individuals and businesses to send money across borders using existing wallets and bank accounts. It provides the technology and network to support peer-to-peer transfers, digital currency-based international settlements, and near-instant settlements across corridors worldwide. The platform offers APIs for currency exchange interoperability between mobile wallets and services, along with a white-labeled web or mobile interface for partners. With a focus on speed, security, and accessibility, Almond FinTech aims to streamline remittances and cross-border payments by leveraging a shared transfer network built on blockchain-enabled infrastructure.

Ieso Digital Health provides online, evidence-based mental health therapy via a digital platform, enabling one-to-one cognitive behavioral therapy delivered by accredited therapists in a virtual, convenient setting. The service covers common mental health conditions such as anxiety, depression, OCD, PTSD, sleep problems, and related issues, and also supports patients with chronic physical health problems, medically unexplained symptoms, and other cognitive concerns. The company uses proprietary technology, including natural language processing and artificial intelligence, to monitor therapist protocol adherence and risk in real time, enabling text-based therapy sessions. It serves health providers including the NHS, private individuals, and employers, expanding access to clinically validated care outside traditional in-person settings.

Ieso Digital Health provides online, evidence-based mental health therapy via a digital platform, enabling one-to-one cognitive behavioral therapy delivered by accredited therapists in a virtual, convenient setting. The service covers common mental health conditions such as anxiety, depression, OCD, PTSD, sleep problems, and related issues, and also supports patients with chronic physical health problems, medically unexplained symptoms, and other cognitive concerns. The company uses proprietary technology, including natural language processing and artificial intelligence, to monitor therapist protocol adherence and risk in real time, enabling text-based therapy sessions. It serves health providers including the NHS, private individuals, and employers, expanding access to clinically validated care outside traditional in-person settings.

Generate Biomedicines, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapeutics through its pioneering platform in Generative Biology. Established in 2018, the company utilizes machine learning to analyze existing proteins, enabling it to understand the principles governing the relationship between genetic sequences and protein structure. This approach facilitates the invention of novel antibodies, peptides, enzymes, receptors, and other protein-based therapeutics optimized for specific biological functions. By harnessing its advanced technology, Generate Biomedicines aims to accelerate drug discovery by generating new biological molecules with significant therapeutic potential. Originally known as Generate Biologics, the company adopted its current name in March 2020 to reflect its expanded focus on biomedicine.

Geneoscopy develops non-invasive diagnostics using stool-derived eukaryotic RNA to prevent, detect, and guide treatment for gastrointestinal diseases. Its platform technology enables early-stage detection of colorectal cancer neoplasms and improves screening compliance.

For over a decade, CloudMosa has been a pioneer in providing remote browser solutions for users in both the consumer and enterprise sector. We used this same technology to develop Puffin, a secure browser product lineup with a proven track record of over 150 million downloads to date. Our products are engineered to meet the strictest cybersecurity standards against zero-day threats. We strive to provide unparalleled security, speed, and efficiency for our clients. We aim to continue developing innovative products for both individual consumers and businesses alike with our years of expertise. The company was founded in 2009 and headquartered in Cupertino, California, USA.

Block Renovation operates a renovation platform that unites design, sourcing, and construction within a single process to simplify home makeovers. The company combines architect-grade design, construction labor, and materials into a streamlined experience, enabling homeowners to plan, design, and build renovations with greater certainty around outcomes, quality, price, and timeline. By integrating design, sourcing, and project management under one roof, Block Renovation aims to improve the renovation journey for homeowners and provide contractors with a clearer, more efficient workflow.

DeepCure Inc. is a biotechnology company based in Boston, Massachusetts, specializing in artificial intelligence-driven drug discovery. Founded in 2018, DeepCure develops innovative solutions for small-molecule drug development, utilizing advanced deep learning algorithms and a proprietary database of chemical compounds. The company offers services such as De-novo Lead Discovery, which employs AI algorithms to assess potential drug candidates from a virtual library, and Artificial Intelligence-driven Lead Optimization, aimed at enhancing drug development processes. Additionally, DeepCure's platform includes a molecular database designed to maximize the diversity and synthesizability of chemical compounds. By integrating AI predictive modeling and a feedback loop, DeepCure focuses on creating effective therapeutics for unmet medical needs, ultimately aiming to expedite the development of novel precision medicines.

Robigo is a biomanufacturing company focused on engineering microbes to develop sustainable crop protection solutions. The company creates precision microbial treatments aimed at enhancing plant health and recovering lost agricultural yields. By leveraging microbial engineering and data science, Robigo produces products that are designed to be more effective while ensuring safety for beneficial microbes, pollinators, humans, and the environment. This approach enables farmers to improve their financial performance while promoting sustainable agricultural practices.

Huckleberry makes behavioral expertise accessible and affordable to all families by combining AI with human experts, starting with children's sleep.

EasyExpunctions.com is a legal platform that offers a cost-effective solution for individuals seeking to erase their criminal records without the need for an attorney. The service employs a unique, patent-pending process that sets it apart from other legal software providers. By focusing exclusively on generating legal documents for reputation management, EasyExpunctions allows users to navigate the expunction process efficiently and affordably. This innovative approach empowers individuals to manage their legal records independently, eliminating the high costs associated with traditional legal services.

Kappa Pay is a fintech platform that utilizes blockchain technology to streamline payment processes for both local and cross-border transactions. The company aims to provide an affordable and reliable solution for individuals and merchants, facilitating seamless payments that resemble the simplicity of sending a message. By focusing on removing friction and barriers in financial transactions, Kappa enables users to send and receive money globally with higher transaction limits, enhancing the overall efficiency of the payment experience.

BetterUp Inc. is a leadership development company that offers an innovative online platform aimed at enhancing the personal and professional growth of individuals and organizations. Founded in 2013 and headquartered in San Francisco, BetterUp specializes in virtual coaching, providing users with personalized guidance through one-on-one sessions with a network of over 3,000 coaches available in 46 languages across more than 90 countries. The platform focuses on fostering mental fitness, career and leadership development, and social connection, thereby enabling employees to develop new behaviors and skills that promote high performance in a rapidly changing work environment. With a client base that includes prominent organizations such as NASA, Google, and Hilton, BetterUp has established itself as a leader in the field of mental health and coaching. The company is supported by a distinguished Science Board composed of experts in positive psychology and human performance, further enhancing its credibility and impact in the industry.

Exo Therapeutics, Inc. is a drug discovery and development company focused on addressing challenging pharmaceutical targets. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary ExoSight platform to create a pipeline of drug candidates that target exosites, which are unique and distal binding pockets on enzymes. This innovative approach aims to reprogram enzyme activity, leading to precise and effective therapeutic outcomes, particularly in oncology and inflammation, while also minimizing potential side effects for patients. Exo Therapeutics is committed to unlocking breakthrough therapeutics through its team of experienced researchers and a deep understanding of complex disease mechanisms.

Angitia Biopharmaceuticals is a global clinical-stage biotechnology company focused on discovering and developing therapeutics for musculoskeletal diseases, specifically targeting bone, muscle, and joint conditions. Through its research and development activities, it aims to deliver breakthrough therapies that address unmet needs and improve outcomes for patients with severe musculoskeletal disorders.

Homee is a technology platform that connects insurers, policyholders, and service providers to streamline home-related services and insurance claims. It supports scheduled and emergency mitigations and repairs, enabling the digital management of the claims-to-service workflow and coordinating a network of restoration contractors, plumbers, electricians, and other professionals. The platform serves homeowners, renters, and property managers by facilitating access to trusted service providers for home repairs, maintenance, and claim-related services.

SemiosBio Technologies Inc. offers innovative pest management solutions for growers of tree fruits, nuts, and grapes globally. The company has developed the Semios platform, which enables real-time monitoring and control of agricultural operations through a comprehensive network of sensors. This platform provides continuous coverage and includes features such as automated pheromones, pest traps, and pest pressure notifications, along with frost monitoring and alerts. Additionally, it evaluates disease risk, monitors irrigation, and assesses soil conditions, helping growers make informed decisions to optimize crop quality while reducing agricultural inputs. Founded in 2009 and headquartered in Vancouver, Canada, Semios also operates locations in Fresno, California; Wenatchee, Washington; and Heerlen, the Netherlands.

Alamar Biosciences, founded in 2018 and headquartered in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that facilitates protein analysis and the creation of antibody technologies. This platform is designed to enhance the diagnosis of diseases, particularly cancer, while also supporting the discovery of new biomarkers. By enabling healthcare providers to detect diseases at an early stage, Alamar Biosciences aims to improve patient outcomes through timely interventions and potential cures.

OptoGlo is a product development company specializing in innovative light and color display technologies. It focuses on creating advanced optical solar signs that combine backlit illumination with solar-powered energy, offering enhanced visibility for advertising and event promotions both day and night. The company utilizes nanotechnology to produce transparent illumination and ultra-high-definition displays, positioning itself as a leader in the industry. In addition to product development, OptoGlo licenses intellectual property and collaborates with partners to establish product distribution companies, expanding the reach of its cutting-edge solutions.

MedRhythms Inc. is a neuro-rehabilitation company that specializes in neurologic music therapy, employing sensors, music, and artificial intelligence to create evidence-based interventions aimed at enhancing walking and overall functional outcomes. Founded in 2015 and headquartered in Portland, Maine, the company addresses the needs of individuals affected by neurological conditions such as traumatic brain injury, stroke, Parkinson’s disease, and Huntington’s disease. By merging music with neuroscience and technology, MedRhythms develops programs that focus on sensorimotor, speech, language, and cognitive rehabilitation goals, allowing patients to leverage music as a therapeutic tool to stimulate brain function and improve their quality of life.

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, and Wolfram syndrome. Founded in 2013 and based in Cambridge, Massachusetts, the company is best known for its investigational therapy AMX0035, a fixed-dose co-formulation of sodium phenylbutyrate and Taurursodiol. This treatment aims to address the energy crisis within mitochondria and the accumulation of toxic, unfolded proteins in the endoplasmic reticulum, both of which contribute to the progression of neurodegenerative conditions. Through its research and development efforts, Amylyx seeks to provide effective solutions to mitigate the suffering caused by these debilitating diseases.

Block Renovation operates a renovation platform that unites design, sourcing, and construction within a single process to simplify home makeovers. The company combines architect-grade design, construction labor, and materials into a streamlined experience, enabling homeowners to plan, design, and build renovations with greater certainty around outcomes, quality, price, and timeline. By integrating design, sourcing, and project management under one roof, Block Renovation aims to improve the renovation journey for homeowners and provide contractors with a clearer, more efficient workflow.

Founded in 2018, Fount Bio is a life science company based in Cambridge, Massachusetts. It specializes in developing biopolymer-based products to enhance tissue rejuvenation, utilizing proprietary bioorthogonal chemistry for targeted delivery of glycopolymers. This approach aims to improve product performance and patient outcomes in aesthetics and medical dermatology.

Linus Health, Inc. is a digital health company based in Waltham, Massachusetts, founded in 2019. It specializes in developing a brain health monitoring platform that utilizes digital screening technology to enhance the assessment and treatment of cognitive and mental health. The platform collects various digital measurements, including voice, speech, gait, cognition, and eye movement, aimed at early detection and diagnosis of brain health issues. Additionally, Linus Health provides clinical decision support and care planning tools, enabling healthcare providers to offer actionable recommendations based on the insights gathered. The company's mission focuses on transforming brain health, making it accessible to individuals worldwide.

Triastek Co. Ltd., established in 2015 and headquartered in Nanjing, China, specializes in the manufacturing of 3D printed pharmaceuticals and related medical equipment. The company offers a range of drugs, including blockbuster and orphan drugs, along with complex drug delivery technologies. Triastek's portfolio includes 3D drug printing services, such as formulation design, equipment, and development methods, with patents secured in key global markets like China, the US, Europe, and Japan. Notably, the company owns Melt Extrusion Deposition (MED), a universally applicable 3D printing technology for solid formulations. Triastek's mission is to revolutionize drug delivery, development, and manufacturing through its proprietary 3D printing technology.

Alentis Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and fibrotic diseases, including liver fibrosis, cirrhosis, and liver cancer. It pursues CLDN1-targeted approaches, developing anti-CLDN1 antibodies and antibody-drug conjugates to modify disease progression in CLDN1-positive cancers. Founded in 2019 and based in Basel, Switzerland, the company advances programs that aim to modulate the immune response and enhance anti-tumor activity while addressing liver-related conditions.

Stealth BioTherapeutics is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of innovative therapies targeting diseases associated with mitochondrial dysfunction. Founded in 2006 and headquartered in George Town, the Cayman Islands, the company’s lead product candidate, Elamipretide, aims to address both rare genetic and common age-related mitochondrial diseases. Additionally, Stealth BioTherapeutics is developing SBT-20, a small peptide designed to stabilize mitochondrial structure and function under oxidative stress, and SBT-272, which is being evaluated for its potential in treating rare neurodegenerative disorders, including amyotrophic lateral sclerosis. By focusing on mitochondrial health, Stealth BioTherapeutics seeks to improve outcomes for patients suffering from these challenging conditions.

Founded in 2017, Coin Metrics provides comprehensive crypto financial intelligence. It offers network data, market data, indexes, and risk management solutions to institutions, empowering them with transparent and actionable insights for informed decision-making.

Nebula Microsystems delivers intelligent and high-performance Analog Products for a wide variety of applications including communication, consumer, industrial, healthcare, and automotive. Power converters, high-speed SERDES, high-performance amplifiers, data converters, and high-power density DC-DC and AC-DC products are among the products offered by Nebula Microsystems.

Catalant is a Boston-based software company that specializes in strategy execution solutions for global enterprises. Founded in 2013, the company's platform enables businesses to break down strategic objectives, access and deploy resources, collaborate, measure value, and improve processes. Catalant's network comprises over 65,000 experts and 1,000 firms, serving more than 30% of the Fortune 100. Additionally, Catalant offers a platform that connects private equity firms with business professionals.

Endolytix is a biotechnology company focused on developing innovative therapeutic solutions to combat antibiotic resistance, particularly in non-tuberculous mycobacterial (NTM) infections. The company's therapies are designed to effectively kill pathogenic bacteria, including those that are multidrug-resistant, thereby enabling healthcare providers to manage infections that are notoriously difficult to treat. Through its novel approaches, Endolytix aims to enhance the efficacy of treatments available for the most resistant antibiotic infections, addressing a critical need within the healthcare industry.

Apnimed, Inc. is a clinical-stage company based in Cambridge, Massachusetts, focused on developing innovative pharmacologic therapies for sleep apnea and related disorders. Founded in 2017, Apnimed aims to address the underlying neurobiological mechanisms that contribute to obstructive sleep apnea (OSA), a serious condition affecting over 20 million Americans. Current treatment options primarily involve positive pressure devices, which can be cumbersome, while Apnimed's approach seeks to provide a simpler, safe, and effective orally dosed medication. The company's therapeutics target both the physiological and symptomatic effects of OSA, with the goal of improving daily functioning and reducing the significant morbidity and mortality associated with this disorder.

Stavvy is a financial technology company that develops digital platforms for mortgage banking professionals. Its core products are Stavvy Connect, which facilitates secure communication and data sharing between lenders and vendors during home loan processes, and Stavvy Notarize, enabling real-time virtual closings and meetings via web conference technology.

PhoreMost is a UK-based drug discovery company specializing in identifying new druggable targets for cancer and other diseases. Established in 2014, it develops Site-Seeker, a platform that systematically uncovers druggable sites in the human genome and links them to useful therapeutic functions in live cells.

Arctic Vision is a clinical-stage specialty ophthalmology company based in China, focused on developing innovative therapies to meet the unmet clinical needs in ophthalmic diseases. The company boasts a leading portfolio of breakthrough technologies aimed at addressing various eye care challenges in China, Asia, and globally. Established by prominent life sciences investors, Arctic Vision is guided by a team of experienced professionals from the ophthalmic industry, who possess extensive knowledge in research and development as well as commercialization of eye care products. The company's efforts include the development of new ophthalmic medicines, particularly gene therapies, that hold significant commercial potential and aim to improve the recovery outcomes for patients with rare ophthalmic conditions.

Monument Bank specializes in serving mass affluent clients such as professionals, property investors, and entrepreneurs. It operates a digital bank offering current accounts and loans for buy-to-let and property investments, with features like video calling for client interaction and online tracking of net worth.

Zhishan Weixin Biotechnology integrates gene-drug research and development to treat genetic and neurodegenerative diseases. The company focuses on the research and development and subversive production of rAAV gene drugs. Zhishan Weixin's therapeutic areas cover blood diseases, rare diseases, and other disease areas.

Rockley Photonics Limited, founded in 2013 and based in London, United Kingdom, specializes in developing silicon photonics technologies for diverse applications. The company focuses on creating integrated optical modules, sensors, and comprehensive solutions that cater to high-volume and dynamic market sectors. Rockley aims to revolutionize mobile health monitoring and machine vision with its next-generation sensing platforms, while also providing high-speed solutions for data communications. By leveraging its innovative photonic integrated circuits and associated modules, Rockley is positioned to address a wide array of vertical applications, believing that photonics will become as ubiquitous as microelectronics in the future. The company combines hardware with supporting electronics, software, application algorithms, and AI platforms, establishing a robust foundation for future developments across multiple industries.

Innodem Neurosciences is a Canadian company founded in 2016 that specializes in developing artificial intelligence-driven mobile software designed to enhance communication for paralyzed and intubated patients through eye movements. The company’s flagship product, Pigio, utilizes advanced eye-tracking technology to facilitate interaction between patients and caregivers. Additionally, Innodem's technology serves as a digital biomarker tool that aids in the diagnosis and monitoring of neurodegenerative diseases. By enabling self-testing and tracking disease progression, the technology allows clinicians to assess treatment effectiveness and make informed adjustments to patient care. Overall, Innodem Neurosciences is dedicated to improving the quality of life for patients and establishing a patient-centric approach in healthcare.

NewAmsterdam Pharma is a clinical-stage biopharmaceutical company focused on researching and developing transformative therapies for cardio-metabolic diseases. Founded in 2019 and based in Naarden, the Netherlands, it is developing obicetrapib, an oral, low-dose CETP inhibitor intended to lower LDL-C and potentially address statin intolerance or residual risk in patients with ASCVD or familial hypercholesterolemia on maximally tolerated statin therapy. The company aims to improve patient care in populations where approved therapies are inadequate or poorly tolerated.

30 Technology is a biopharmaceutical platform developer focused on improving the lives of patients facing serious and life-threatening medical conditions. The company specializes in harnessing the therapeutic potential of nitric oxide to create innovative treatments that enhance patient healing and bolster defense mechanisms. By facilitating the development of new models of care, 30 Technology aims to provide healthcare professionals with effective tools to address a range of critical medical issues, ultimately striving to advance patient outcomes and quality of life.

Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company specializes in providing affordable primary care through a chat-based interface that integrates artificial intelligence with human clinicians. This approach leverages advanced machine learning tools to streamline patient interactions and enhance diagnostic accuracy. By creating a responsive learning healthcare system, Curai Health aims to make high-quality primary care accessible to everyone, reducing the overall cost of care delivery. The service is available directly to consumers and can also be accessed through enterprise partnerships, emphasizing its commitment to improving healthcare accessibility and affordability.

Founded in 2018, DEEPEXI is a leading provider of enterprise-level digital transformation services. It offers business consulting, solutions, products, and technology research & development based on advanced internet architecture. With over 160 employees across Beijing, Guangzhou, Shenzhen, Nanjing, and Chengdu, the company specializes in scalable business intelligence services that integrate 5G, IoT, big data, AI, and cloud computing technologies.

Tallac Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative immunotherapies for cancer patients. Founded in 2018 and headquartered in Burlingame, California, the company specializes in creating conjugates of antibodies combined with potent toll-like receptor agonists. This approach aims to activate both innate and adaptive immunity, enabling targeted immune responses against various solid tumor malignancies. Through its advanced therapies, Tallac Therapeutics seeks to enhance the immune system's ability to combat cancer more effectively.

Founded in 2012, Neuroelectrics is a Barcelona-based company specializing in digital brain health technologies. It develops wireless EEG devices and non-invasive electrical brain stimulation tools with up to 32 channels, along with accompanying software and research services. The company aims to monitor and enhance brain health by measuring and modifying brain function.

CellCentric Ltd. is a biotechnology company based in Cambridge, United Kingdom, focused on developing innovative cancer therapeutics. Established in 2003, the company specializes in small-molecule inhibitors targeting p300, CBP, and specific deubiquitinase enzymes, which play a crucial role in regulating gene expression in cancer cells. Its primary research program addresses prostate cancer, a significant cause of male mortality, by modulating the androgen receptor pathway and potentially overcoming resistance mechanisms found in existing treatments. Additionally, CellCentric's products have applications in treating other cancers, including non-small cell lung cancer, breast cancer, and colon cancer. The company's approach aims to provide targeted therapies for various malignancies, addressing unmet medical needs in the oncology field.

InCarda Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cardiovascular diseases. Founded in 2009 and based in Newark, California, the company specializes in a novel inhaled treatment approach to manage acute cardiovascular conditions. Its lead product, InRhythm, is an inhaled formulation of an antiarrhythmic drug designed to treat paroxysmal atrial fibrillation quickly, allowing patients to administer the therapy in various settings, such as at home or work. By delivering medication directly to cardiac tissue, InCarda's therapy aims to provide effective treatment for atrial arrhythmias with a simplified approach. The company has completed Phase 1 clinical trials and is currently advancing its lead product through Phase 2 trials.

Founded in 2011, Revolo Biotherapeutics specializes in developing therapies for autoimmune and allergic diseases. Its innovative approach aims to achieve superior long-term remission with less frequent dosing, without suppressing the immune system.

LeLe Ketang is an online education platform based in Beijing, China, specializing in K-12 education services. Founded in 2014, the company primarily focuses on providing online training courses for primary and secondary school students, emphasizing subjects such as math and language. LeLe Ketang utilizes innovative teaching methods, including three-minute video lectures and gamification elements, to engage students effectively. Additionally, the platform offers personalized learning experiences through one-on-one interactions, enhancing the educational journey for its users.

Prescryptive Health operates a digital platform that enhances prescription drug market transparency. It provides unbiased pricing and cost information to empower patients, payers, and providers with real-time insights at the point of care.

F2G Ltd is a biotechnology company focused on developing innovative therapies for serious fungal infections. Founded in 1998 and based in Manchester, United Kingdom, F2G primarily works on its F3 series of anti-mold compounds, specifically targeting antifungal agents against Aspergillus and other filamentous molds. Utilizing proprietary genomics technology known as MycoBank, the company identifies essential gene targets in fungi, which informs its drug development process. F2G has diversified its approach to include chemistry-driven discovery, leveraging a strong development team to advance its patented compounds. The company's efforts aim to address difficult-to-treat fungal pathogens that pose significant mortality risks, particularly for immunocompromised patients, thereby enhancing treatment options in the pharmaceutical industry.

Vesigen Therapeutics is a biotechnology company focused on delivering therapeutic payloads into intracellular targets using ARMMs (ARRDC1 Mediated Microvesicles) extracellular vesicle delivery technology. It designs and develops medicines that enable intracellular delivery and address barriers related to cell membranes and degradative systems, enabling a broad range of payloads to reach target cells. Its ARMMs platform supports delivery of RNA-based therapies, proteins, and gene-editing complexes such as Cas9/gRNA directly into the cytoplasm, expanding the universe of druggable targets and enabling new treatments for unmet medical needs. Vesigen Therapeutics aims to advance intracellular drug modalities to widen therapeutic possibilities across diseases. It was incorporated in 2020 and is based in Cambridge, Massachusetts.

Arctic Vision is a clinical-stage specialty ophthalmology company based in China, focused on developing innovative therapies to meet the unmet clinical needs in ophthalmic diseases. The company boasts a leading portfolio of breakthrough technologies aimed at addressing various eye care challenges in China, Asia, and globally. Established by prominent life sciences investors, Arctic Vision is guided by a team of experienced professionals from the ophthalmic industry, who possess extensive knowledge in research and development as well as commercialization of eye care products. The company's efforts include the development of new ophthalmic medicines, particularly gene therapies, that hold significant commercial potential and aim to improve the recovery outcomes for patients with rare ophthalmic conditions.

neoX Biotech is a Beijing-based biotechnology company founded in 2018 that specializes in the development of antigen-based cancer vaccines. By integrating artificial intelligence with biophysics, neoX Biotech focuses on the discovery and development of macromolecular and multispecific drugs, primarily in the field of immuno-oncology. The company has established a platform for early therapeutic discovery, which includes neoantigen prediction and T cell receptor screening, as well as the characterization of protein-protein interactions. This innovative approach aims to provide effective treatments for cancer patients by advancing drug research and development.

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s disease, and Wolfram syndrome. Founded in 2013 and based in Cambridge, Massachusetts, the company is best known for its investigational therapy AMX0035, a fixed-dose co-formulation of sodium phenylbutyrate and Taurursodiol. This treatment aims to address the energy crisis within mitochondria and the accumulation of toxic, unfolded proteins in the endoplasmic reticulum, both of which contribute to the progression of neurodegenerative conditions. Through its research and development efforts, Amylyx seeks to provide effective solutions to mitigate the suffering caused by these debilitating diseases.

Big Health is a digital therapeutics company headquartered in London, United Kingdom, that specializes in developing and marketing innovative behavioral health programs. The company's flagship product, Sleepio, is a digital sleep improvement program that employs Cognitive Behavioral Therapy techniques to address and personalize sleep disorders. By offering a fully automated healthcare portal, Big Health delivers highly personalized digital therapeutics and behavioral programs aimed at tackling various mental health issues. Their approach combines medical consultation with user-friendly technology, enabling individuals to effectively manage and overcome sleep-related disorders in an efficient manner.

Prilenia is a clinical-stage biotechnology company focused on developing innovative treatments for neurodegenerative and neurodevelopmental disorders. Founded in 2018 and operating from locations in Israel, the Netherlands, and Boston, the company’s primary asset is Pridopidine, an oral drug candidate noted for its established safety profile. Pridopidine demonstrates potential in treating various movement disorders and neurodegenerative diseases that affect both adults and children, aiming to help healthcare institutions preserve functional capacity in patients, including those undergoing early hemodialysis.

Heyuan Biotechnology is a biotechnology company focusing on the field of gene therapy services. They offer gene therapy vectors, gene function research, drug targets, and efficacy for the basic research of gene therapy research, among other services.